Development Agreement With Nurron Pharmaceuticals To Develop Therapy For Parkinson's Disease

Daewoong Pharma

25/05/2023 12:43

May 25 (Reuters) - Hanall Biopharma Co Ltd  009420.KS :
    * HANALL BIOPHARMA AND DAEWOONG PHARMACEUTICAL ENTER INTO
CO-DEVELOPMENT AGREEMENT WITH NURRON PHARMACEUTICALS TO DEVELOP
THERAPY FOR PARKINSON'S DISEASE
    * HANALL BIOPHARMA CO LTD- HANALL BIOPHARMA AND DAEWOONG
PHARMACEUTICAL WILL CO-DEVELOP NURRON PHARMACEUTICALS' NOVEL
INVESTIGATIONAL COMPOUNDS
    * HANALL BIOPHARMA CO LTD- PHASE 1 CLINICAL TRIAL IS
EXPECTED TO
BE INITIATED IN 2023
    * HANALL BIOPHARMA CO LTD- CO, DAEWOONG PHARMACEUTICAL WILL
CONTINUE TO EXPLORE POTENTIAL OF ATH-399A IN OTHER
NEURODEGENERATIVE DISEASES

Source text for Eikon:  ID:nPn2zPVZDa 
Further company coverage:  009420.KS 

 ((Reuters.Briefs@thomsonreuters.com;))